<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041222</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 333611- CS1</org_study_id>
    <nct_id>NCT01041222</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations</brief_title>
  <acronym>SOD-1</acronym>
  <official_title>A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of ISIS 333611 Administered Intrathecally to Patients With Familial Amyotrophic Lateral Sclerosis Due to Superoxide Dismutase 1 Gene Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety, tolerability and pharmacokinetics of single doses of ISIS
      333611 administered into the spinal canal as 12 hour infusions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the safety, tolerability, and pharmacokinetics of single doses of ISIS
      333611 administered as 12-hour intrathecal infusions. Four dose levels (0.15, 0.5, 1.5 and 3
      mg) will be evaluated sequentially. The volume of the infusion is 0.25 mL/12 hours. Each dose
      level will be studied in a cohort of 8 patients where 6 are randomized to active treatment
      with ISIS 333611 and 2 are randomized to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety, tolerability, and pharmacokinetics of four dose levels of ISIS 333611</measure>
    <time_frame>Safety analysis for dose escalation after Study Day 8</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Familial Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (phosphate buffered saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 333611</intervention_name>
    <description>5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Placebo (phosphate buffered saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs of weakness attributed to ALS.

          -  Familial ALS with a documented SOD1 gene mutation.

          -  Age 18 years or older.

          -  Capable of providing informed consent and willing to comply with trial procedures and
             time commitments.

          -  Vital capacity (VC) at least 50% predicted value for gender, height and age at
             screening and not using invasive respiratory support.

          -  If taking riluzole, patients must be on stable dosage for at least 30 days prior to
             starting the study and expect to remain at that dosage until the end of the study.

          -  Medically able to undergo temporary insertion of intrathecal catheter.

          -  Normal test results for coagulation parameters.

        Exclusion Criteria:

          -  Treatment with another investigational drug for ALS (e.g. pyrimethamine, ceftriaxone,
             lithium, tamoxifen, arimoclomol, high dose creatine, biological agent, or device
             within 1-month of Screening or 5 half-lives of study agent, whichever is longer. No
             prior treatment with siRNA, cell transplant, or gene therapy is allowed.

          -  Dosing in ISIS 333611-CS1 in a previous dose cohort within 60 days of screening.

          -  Presence of any of the following clinical conditions:

               1. Drug abuse or alcoholism within one year of the Screening visit.

               2. Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic function, or
                  active infectious disease.

               3. Documented history of HIV infection.

               4. Unstable psychiatric illness defined as psychosis or untreated major depression
                  within 90 days of the Screening Visit.

          -  Any condition that may impact intrathecal infusion including:

               1. History of structural spinal disease including tumors and hyperplasia.

               2. Presence of an implanted shunt for the drainage of CSF or an implanted CNS
                  catheter.

               3. Clinically significant abnormalities in hematology or clinical chemistry
                  parameters as assessed by the Site Investigator during the Screening visit.

               4. Ongoing medical condition that according to the Site Investigator would interfere
                  with the conduct and assessments of the study. Examples are medical disability
                  (e.g., severe degenerative arthritis, compromised nutritional state, peripheral
                  neuropathy) that would interfere with the assessment of safety and efficacy of
                  study material or device performance, or would compromise the ability of the
                  patient to undergo study procedures.

               5. ALT or AST &gt;/= 3 x ULN, unless discussed with and approved by the Medical
                  Monitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit Cudkowicz, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Miller, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital-East, Neurology Clinical Trials Unit</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2009</study_first_submitted>
  <study_first_submitted_qc>December 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2009</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial ALS</keyword>
  <keyword>ALS</keyword>
  <keyword>SOD1 Protein</keyword>
  <keyword>ISIS 333611</keyword>
  <keyword>SOD1Rx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Superoxide Dismutase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

